Review





Similar Products

94
Thermo Fisher copy number variation batf hs00924966 cn
Copy Number Variation Batf Hs00924966 Cn, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/copy number variation batf hs00924966 cn/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
copy number variation batf hs00924966 cn - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc anti batf
Anti Batf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti batf/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
anti batf - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc unconjugated anti batf rabbit mab
Unconjugated Anti Batf Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/unconjugated anti batf rabbit mab/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
unconjugated anti batf rabbit mab - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc anti batf rabbit mab
Anti Batf Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti batf rabbit mab/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
anti batf rabbit mab - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc batf
Tumor <t>induced</t> <t>PD-L1</t> expression in neutrophils enhances IL31 secretion of CD8 + T cells. (A) IL31 and OSM mRNA level in CD8 + T cells after co-cultured neutrophils and GC cells. (B) TIM-3, PD-1 and IL31 mRNA level in CD8 + T cells treated with IL2 and Anti-CD3/CD28 antibody. (C) IL31 mRNA and protein level in CD8 + T cells co-cultured with neutrophils treated with BMP5 and PD-L1 inhibitor (Atezolizumab). (D) Schematic of PD-1/PD-L1 signaling pathway in CD8 + T cells. (E) <t>BATF</t> mRNA and protein level in CD8 + T cells treated with IL2 and Anti-CD3/CD28 antibody for 0 day and 14 days. (F) BATF mRNA and protein level in CD8 + T cells after co-cultured neutrophils and GC cells. (G) IL31 mRNA and protein level in CD8 + T cells when BATF was up-regulated or down-regulated. (H) Dual-Luciferase Reporter Assay analysis for BATF-binding IL31 promoter. (I) p-PI3K, PI3K, p-AKT, AKT, p-P27, P27, CCNE2, PD-L1, and PD-L2 expression in MKN28 cells treated with supernatant of CD8 + T cells (J) mIF staining analysis of correlation of OSMR, CD15, CD8, and IL31 in tumor samples from patients in Cohort 2. (**, P < 0.01).
Batf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/batf/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
batf - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc anti batf antibody
A Fosl2 and HTLV-1 Tax enrichment (ChIP-seq) in HCT-4 cells and chromatin accessibility (ATAC-seq) in HTLV-1-infected CD4 + T cells in patients with HAM, highlighting the HAM-characteristic OCR. Genomic DNA from HCT-4 cells prior to immunoprecipitation served as input control. ChIP-seq and ATAC-seq peaks were visualized with IGV (data range: ChIP-seq, 0-30; ATAC-seq, 0-100). B Enrichment analysis of transcription factor motifs in ChIP-seq with Fosl2 using the HOMER algorithm. Motifs are ranked by -log10(P). Statistical analysis was performed using a one-sided hypergeometric test. Nominal P values are reported. C Enhancer assays using the MAP3K8 promoter and HAM-characteristic OCR at the MAP3K8 locus. Relative luciferase activity for Fosl2 with partner factors <t>(c-Jun,</t> <t>JunB,</t> <t>BATF,</t> and BATF3) was examined. Data are presented as mean values + SD. Statistical significance was assessed by one-way ANOVA followed by two-sided Tukey’s honestly significant difference (HSD) test for multiple comparisons. Asterisks indicate statistical significance (*** P < 0.001). n = 3, 4, or 5 biologically independent experiments, each performed on separate days using independently transfected HEK293 cells. D Enhancer assays using the MAP3K8 promoter and HAM-characteristic OCR, with Fosl2, c-Jun, and HTLV-1 Tax. Yellow arrows indicate OCR orientation (5’ → 3’ or 3’ → 5’). Data are presented as mean values + SD. Statistical significance was assessed by one-way ANOVA followed by two-sided Tukey’s HSD test for multiple comparisons. Exact P value are as follows: MAP3K8 promoter with Fosl2, c-Jun, and HTLV-1 Tax vs MAP3K8 promoter and HAM-characteristic OCR (5’ → 3’) with Fosl2, c-Jun, and HTLV-1 Tax, P = 0.000010, MAP3K8 promoter with Fosl2, c-Jun, and HTLV-1 Tax vs MAP3K8 promoter and HAM-characteristic OCR (3’ → 5’) with Fosl2, c-Jun, and HTLV-1 Tax, P = 0.000021. Asterisks indicate statistical significance (*** P < 0.001). n = 4 or 7 biologically independent experiments, each performed on separate days using independently transfected HEK293 cells. E Representative histograms depicting chromatin accessibility at the MAP3K8 locus, as determined by ATAC-seq analysis, across various CD4⁺ T cell populations: resting normal CD4⁺ T cells, HAM_D subset, CD4⁺ T cells transiently expressing HTLV-1 Tax for 7 days via a lentiviral system (Tax-cell), and CD4⁺ T cells activated with anti-CD3/CD28 antibodies ( GSM5554060 ). The highlighted region shows HAM-characteristic OCR. ATAC-seq peaks were visualized with IGV (data range: 0-100).
Anti Batf Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti batf antibody/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
anti batf antibody - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


Tumor induced PD-L1 expression in neutrophils enhances IL31 secretion of CD8 + T cells. (A) IL31 and OSM mRNA level in CD8 + T cells after co-cultured neutrophils and GC cells. (B) TIM-3, PD-1 and IL31 mRNA level in CD8 + T cells treated with IL2 and Anti-CD3/CD28 antibody. (C) IL31 mRNA and protein level in CD8 + T cells co-cultured with neutrophils treated with BMP5 and PD-L1 inhibitor (Atezolizumab). (D) Schematic of PD-1/PD-L1 signaling pathway in CD8 + T cells. (E) BATF mRNA and protein level in CD8 + T cells treated with IL2 and Anti-CD3/CD28 antibody for 0 day and 14 days. (F) BATF mRNA and protein level in CD8 + T cells after co-cultured neutrophils and GC cells. (G) IL31 mRNA and protein level in CD8 + T cells when BATF was up-regulated or down-regulated. (H) Dual-Luciferase Reporter Assay analysis for BATF-binding IL31 promoter. (I) p-PI3K, PI3K, p-AKT, AKT, p-P27, P27, CCNE2, PD-L1, and PD-L2 expression in MKN28 cells treated with supernatant of CD8 + T cells (J) mIF staining analysis of correlation of OSMR, CD15, CD8, and IL31 in tumor samples from patients in Cohort 2. (**, P < 0.01).

Journal: Neoplasia (New York, N.Y.)

Article Title: OSMR coordinates a self-perpetuating circuit linking chemoresistance and neutrophil-driven immunosuppression in gastric cancer

doi: 10.1016/j.neo.2026.101279

Figure Lengend Snippet: Tumor induced PD-L1 expression in neutrophils enhances IL31 secretion of CD8 + T cells. (A) IL31 and OSM mRNA level in CD8 + T cells after co-cultured neutrophils and GC cells. (B) TIM-3, PD-1 and IL31 mRNA level in CD8 + T cells treated with IL2 and Anti-CD3/CD28 antibody. (C) IL31 mRNA and protein level in CD8 + T cells co-cultured with neutrophils treated with BMP5 and PD-L1 inhibitor (Atezolizumab). (D) Schematic of PD-1/PD-L1 signaling pathway in CD8 + T cells. (E) BATF mRNA and protein level in CD8 + T cells treated with IL2 and Anti-CD3/CD28 antibody for 0 day and 14 days. (F) BATF mRNA and protein level in CD8 + T cells after co-cultured neutrophils and GC cells. (G) IL31 mRNA and protein level in CD8 + T cells when BATF was up-regulated or down-regulated. (H) Dual-Luciferase Reporter Assay analysis for BATF-binding IL31 promoter. (I) p-PI3K, PI3K, p-AKT, AKT, p-P27, P27, CCNE2, PD-L1, and PD-L2 expression in MKN28 cells treated with supernatant of CD8 + T cells (J) mIF staining analysis of correlation of OSMR, CD15, CD8, and IL31 in tumor samples from patients in Cohort 2. (**, P < 0.01).

Article Snippet: The membranes were blocked with 5% non-fat milk in TBST for 1 hour at room temperature, followed by an overnight incubation at 4°C with primary antibodies (OSMR (Abcam, #ab315388), CCNE2 (Abcam, #ab40890), β-actin (CST, #4967), PI3K (P85) (CST, #4292), p-PI3K (p-P85) (Abcam, #ab278545), AKT (CST, #9272), p-AKT (CST, #4060), P27 (CST, #2552), p-P27 (Abcam, #ab62364), FLAG (CST, #14793), BMP5 (Proteintech, #13253-1-AP), Ub (CST, #20326), TRIM2 (Proteintech, #20356-1-AP), GATA3 (CST, #5852), p-SMAD1/5 (CST, #9516), SMAD5 (CST, #12534), PD-L1 (CST, #13684), BATF (CST, #8638), IL-31 (abcam, #ab62579)), which were diluted in accordance with the manufacturer's instructions.

Techniques: Expressing, Cell Culture, Luciferase, Reporter Assay, Binding Assay, Staining

A Fosl2 and HTLV-1 Tax enrichment (ChIP-seq) in HCT-4 cells and chromatin accessibility (ATAC-seq) in HTLV-1-infected CD4 + T cells in patients with HAM, highlighting the HAM-characteristic OCR. Genomic DNA from HCT-4 cells prior to immunoprecipitation served as input control. ChIP-seq and ATAC-seq peaks were visualized with IGV (data range: ChIP-seq, 0-30; ATAC-seq, 0-100). B Enrichment analysis of transcription factor motifs in ChIP-seq with Fosl2 using the HOMER algorithm. Motifs are ranked by -log10(P). Statistical analysis was performed using a one-sided hypergeometric test. Nominal P values are reported. C Enhancer assays using the MAP3K8 promoter and HAM-characteristic OCR at the MAP3K8 locus. Relative luciferase activity for Fosl2 with partner factors (c-Jun, JunB, BATF, and BATF3) was examined. Data are presented as mean values + SD. Statistical significance was assessed by one-way ANOVA followed by two-sided Tukey’s honestly significant difference (HSD) test for multiple comparisons. Asterisks indicate statistical significance (*** P < 0.001). n = 3, 4, or 5 biologically independent experiments, each performed on separate days using independently transfected HEK293 cells. D Enhancer assays using the MAP3K8 promoter and HAM-characteristic OCR, with Fosl2, c-Jun, and HTLV-1 Tax. Yellow arrows indicate OCR orientation (5’ → 3’ or 3’ → 5’). Data are presented as mean values + SD. Statistical significance was assessed by one-way ANOVA followed by two-sided Tukey’s HSD test for multiple comparisons. Exact P value are as follows: MAP3K8 promoter with Fosl2, c-Jun, and HTLV-1 Tax vs MAP3K8 promoter and HAM-characteristic OCR (5’ → 3’) with Fosl2, c-Jun, and HTLV-1 Tax, P = 0.000010, MAP3K8 promoter with Fosl2, c-Jun, and HTLV-1 Tax vs MAP3K8 promoter and HAM-characteristic OCR (3’ → 5’) with Fosl2, c-Jun, and HTLV-1 Tax, P = 0.000021. Asterisks indicate statistical significance (*** P < 0.001). n = 4 or 7 biologically independent experiments, each performed on separate days using independently transfected HEK293 cells. E Representative histograms depicting chromatin accessibility at the MAP3K8 locus, as determined by ATAC-seq analysis, across various CD4⁺ T cell populations: resting normal CD4⁺ T cells, HAM_D subset, CD4⁺ T cells transiently expressing HTLV-1 Tax for 7 days via a lentiviral system (Tax-cell), and CD4⁺ T cells activated with anti-CD3/CD28 antibodies ( GSM5554060 ). The highlighted region shows HAM-characteristic OCR. ATAC-seq peaks were visualized with IGV (data range: 0-100).

Journal: Nature Communications

Article Title: Chromatin remodeling enhances MAP3K8 expression in HAM: a key pathogenesis for therapeutic intervention

doi: 10.1038/s41467-025-64836-7

Figure Lengend Snippet: A Fosl2 and HTLV-1 Tax enrichment (ChIP-seq) in HCT-4 cells and chromatin accessibility (ATAC-seq) in HTLV-1-infected CD4 + T cells in patients with HAM, highlighting the HAM-characteristic OCR. Genomic DNA from HCT-4 cells prior to immunoprecipitation served as input control. ChIP-seq and ATAC-seq peaks were visualized with IGV (data range: ChIP-seq, 0-30; ATAC-seq, 0-100). B Enrichment analysis of transcription factor motifs in ChIP-seq with Fosl2 using the HOMER algorithm. Motifs are ranked by -log10(P). Statistical analysis was performed using a one-sided hypergeometric test. Nominal P values are reported. C Enhancer assays using the MAP3K8 promoter and HAM-characteristic OCR at the MAP3K8 locus. Relative luciferase activity for Fosl2 with partner factors (c-Jun, JunB, BATF, and BATF3) was examined. Data are presented as mean values + SD. Statistical significance was assessed by one-way ANOVA followed by two-sided Tukey’s honestly significant difference (HSD) test for multiple comparisons. Asterisks indicate statistical significance (*** P < 0.001). n = 3, 4, or 5 biologically independent experiments, each performed on separate days using independently transfected HEK293 cells. D Enhancer assays using the MAP3K8 promoter and HAM-characteristic OCR, with Fosl2, c-Jun, and HTLV-1 Tax. Yellow arrows indicate OCR orientation (5’ → 3’ or 3’ → 5’). Data are presented as mean values + SD. Statistical significance was assessed by one-way ANOVA followed by two-sided Tukey’s HSD test for multiple comparisons. Exact P value are as follows: MAP3K8 promoter with Fosl2, c-Jun, and HTLV-1 Tax vs MAP3K8 promoter and HAM-characteristic OCR (5’ → 3’) with Fosl2, c-Jun, and HTLV-1 Tax, P = 0.000010, MAP3K8 promoter with Fosl2, c-Jun, and HTLV-1 Tax vs MAP3K8 promoter and HAM-characteristic OCR (3’ → 5’) with Fosl2, c-Jun, and HTLV-1 Tax, P = 0.000021. Asterisks indicate statistical significance (*** P < 0.001). n = 4 or 7 biologically independent experiments, each performed on separate days using independently transfected HEK293 cells. E Representative histograms depicting chromatin accessibility at the MAP3K8 locus, as determined by ATAC-seq analysis, across various CD4⁺ T cell populations: resting normal CD4⁺ T cells, HAM_D subset, CD4⁺ T cells transiently expressing HTLV-1 Tax for 7 days via a lentiviral system (Tax-cell), and CD4⁺ T cells activated with anti-CD3/CD28 antibodies ( GSM5554060 ). The highlighted region shows HAM-characteristic OCR. ATAC-seq peaks were visualized with IGV (data range: 0-100).

Article Snippet: Anti-c-Jun antibody (9165S, Cell Signaling Technology) Anti-JunB antibody (sc-8051, Santa Cruz Biotechnology) Anti-BATF antibody (8638 T, Cell Signaling Technology) Anti-BATF3 antibody (GTX130125, Gene Tex) Anti-Tax antibody (LT-4, kindly gifted by Dr. Yuetsu Tanaka) Anti-Rabbit IgG (whole molecule)-Peroxidase antibody (A9169, Sigma-Aldrich) Anti-Mouse IgG (whoke molecule)-Peroxidase antibody (A5278, Sima-Aldrich) ECL Prime Western Blotting Detection Reagent (Cytiva, Little Chalfront, England)

Techniques: ChIP-sequencing, Infection, Immunoprecipitation, Control, Luciferase, Activity Assay, Transfection, Expressing